Other Events. As previously disclosed, on November 21, 2025, Tango Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Sales Agent”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), through the Sales Agent. The Company previously filed a registration state…

of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in the filing unless specifically stated so therein.

null — Dr. Weber: Dr. Weber has left the company with a separation agreement providing severance and other benefits.

Executive Chair — Dr. Barbara Weber: Dr. Barbara Weber's employment as Executive Chair ended, and she resigned from all officer and board member positions.

Director — Robert Azelby: The company appointed Robert Azelby as a new director and member of the Compensation Committee and NCG Committee.

Entry into a Material Definitive Agreement. On June 9, 2026, Tango Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives (the “Representatives”) to the several underwriters named in the Underwriting Agreement (collectively, the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 18,166,667 shares (the “Firm Shares”) of the Company’s common st…

Other Events. On June 8, 2026, the Company disclosed initial safety and efficacy data from its Phase 1/2 combination trial evaluating vopimetostat in combination with RAS(ON) inhibitors from Revolution Medicines, Inc. in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (“PDAC”). As of the cutoff date of May 28, 2026, 59 patients with previously treated MTAP-deleted and RAS-mutant PDAC or non-small cell lung cancer (“NSCLC”), were treated with a vopimetosta…

Director — Alexis Borisy, Kanishka Pothula: Two directors resigned from the board and their roles.

Results of Operations and Financial Condition. On May 13, 2026, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to

Chief Financial Officer, principal accounting officer and principal financial officer — Daniella Beckman: Ms. Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer.

Chief Financial Officer — Daniella Beckman: The CFO is departing and a new CFO has been appointed.

Results of Operations and Financial Condition. On March 5, 2026, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to

President and CEO — Barbara Weber, M.D.: Dr. Barbara Weber retired and was succeeded by Dr. Malte Peters as President and CEO.

and 7.01 of this Current Report on Form 8-K and Exhibit 99.1 as well as Exhibit 99.2 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in the filing, unless specifically stated so therein. Cautiona…

Director — Sung H. Lee: The Board appointed Sung H. Lee as a director to fill a newly created vacancy.

Termination of a Material Definitive Agreement. As previously disclosed, on September 1, 2022, the Company entered into an Open Market Sales Agreement SM (the “Jefferies Sales Agreement”) with Jefferies LLC (“Jefferies”), as sales agent, to sell, at its option, shares of the Company’s common stock, $0.001 par value per share, from time to time, through Jefferies, as the Company’s sales agent (the “2022 ATM Program”). Pursuant to the Registration Statement on Form S-3 (File No. 333-267224) fil…

Entry into a Material Definitive Agreement. On November 21, 2025, Tango Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, shares of the Company’s common stock, $0.001 par value per share (the “Shares”), through the Agent, as sales agent (the “ATM Offering”). Pursuant to the prospectus supplement (the “ATM Prospectus Supplement”) filed with…

Results of Operations and Financial Condition. On November 4, 2025, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to

The PIPE Shares issued and sold in the Private Placement are being offered pursuant to Section 4(a)(2) of the Securities Act, and Rule 506(b) of Regulation D as promulgated by the SEC under the Securities Act. The Company relied on this exemption from registration for the Private Placement based in part on the representations made by the Purchaser, including the representations with respect to the Purchaser’s investment intent. The securities were not issued through any general solicitation o…

Entry into a Material Definitive Agreement. (a) Registered Direct Offering On October 23, 2025, Tango Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative to the several underwriters named in the Underwriting Agreement (collectively, the “Underwriters”), relating to an underwritten offering (the “Registered Direct Offering”) of (i) 21,023,337 shares (the “Shares”) of the Company’s common stock, $0…

Results of Operations and Financial Condition. The information set forth in

Chief Legal and Compliance Officer and Corporate Secretary — Douglas Barry: Resigned to pursue another opportunity.

Results of Operations and Financial Condition. On August 5, 2025, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to

Results of Operations and Financial Condition. On May 12, 2025, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to

Results of Operations and Financial Condition. On February 27, 2025, Tango Therapeutics, Inc. (“Tango” or the “Company”) issued a press release relating to its results of operations and financial condition for the quarter and full year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to